ulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance (PVR) and arterial pressure that can lead to right heart failure and death. [1] [2] [3] [4] The diagnosis and management of PAH has undergone signifi cant change since the National Institutes of Health (NIH) conducted the first registry of primary pulmonary hypertension (idiopathic PAH [IPAH]) in the early 1980s. 5, 6 Although clinical trials have led to advances in therapy for PAH, 7-19 the disease remains progressive and often fatal. Although clinical trials remain the standard 1 for evaluating potential new therapies, further progress will require better understanding of the patient population and outcomes of treatment as 
a mildly increased pulmonary capillary wedge pressure (PCWP) (16) (17) (18) mm Hg) were included in the REV EAL Registry, and were compared with those meeting the traditional hemodynamic definition (PCWP Յ 15 mm Hg). In addition, children were included, making this the fi rst registry to include a substantial number of pediatric patients. Longitudinal objectives are to evaluate differences in outcome according to WHO group I PAH subgroups, functional status, and hemodynamic criteria; to identify predictors of short-and long-term outcomes; and to assess the relationship between PAH medications and outcomes. In this report, we describe baseline demo graphics and treatment in 2,967 adult and pediatric patients diagnosed with WHO group I PAH.
Materials and Methods

Design Overview
The REVEAL Registry was designed by an independent Steering Committee, which oversaw study execution, data analysis, and reporting of the results. The design of the registry has been described in detail. 26 The registry uses a multicenter prospective cohort des ign involving 54 centers in the United States (including 21 sites enrolling pediatric patients). The centers incl ude diverse university-affi liated and community hospitals. Each of the four US Census Regions was represented.
Between March 2006 and September 2007, consecutive patients with suspected or confi rmed WHO group I PAH were screened. Patients were offered participation in the study if they met inclusion criteria described below. Since the goal was to describe current practice and outcomes, the registry is entirely observational and, although a right heart catheterization (RHC) was necessary to meet the study inclusion criteria, the protocol did not direct patient management or require a prescribed visit schedule. All patients will be prospectively tracked through December 2012, with a minimum follow-up of 5 years. The protocol was reviewed and approved by the institutional review board of each participating center.
Setting and Participants
Patients with newly or previously diagnosed PAH were eligible for enrollment if they met the modifi ed defi nition of WHO group I PAH 27 and prespecifi ed hemodynamic criteria by RHC. The defi nition of WHO group I 27 includes patients with PAH that is idiopathic, familial, or associated with collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, drugs or toxins, HIV infection, and miscellaneous conditions (such as splenectomy or hemoglobinopathies). Classifi cation into these subgroups of WHO group I was assigned by the investigator enrolling the subject into the registry, based upon their impression of the most likely cause of the patient's PAH. Patients participating in clinical trials were eligible for enrollment. Patients were ineligible if they were younger than 3 months at the time of enrollment. Eligible patients were asked to provide written informed consent (and assent when appropriate) and the Health Insurance Portability and Accountability Act authorization according to International Conference on Harmonization guidance for good clinical practice. Patients were classifi ed with newly diagnosed PAH if the diagnostic RHC occurred within the previous 90 days. applied in current clinical practice. Recent reviews have emphasized the need for prospective studies of the clinical course and management of PAH. [20] [21] [22] Registries conducted since the NIH study have enhanced our understanding of select aspects of PAH. A network of 17 French university hospitals reported observations from a registry of 674 adults with PAH and described the minimum prevalence and incidence, as well as the clinical and hemodynamic characteristics, of this group. 23 The Surveillance of North American Pulmonary Hypertension 24 and Surveillance of Pulmonary Hypertension in America 25 registries focused on evaluating the association of environmental factors, particularly ano rexigens, with PAH.
A large prospective study of current US practice is needed to provide a foundation for new clinical and scientifi c advances. The Registry to EValuate Early And Long-term PAH disease management (REVEAL Registry) was initiated to characterize the demographics, clinical course, hemodynamic features, and disease management of a US patient population with World Health Organization (WHO) group I PAH. In order to be relevant to clinical practice, this study purposefully included geographically distributed patients with a broad defi nition of WHO group I PAH on any current treatment. Patients with pulmonary hypertension and
Data Collection
Data were collected using electronic data capture (eDC), beginning with the initial screening visit. The baseline assessment included medical history. Data collected retrospectively included time of diagnosis and symptom onset, specialty of evaluating physicians, tests used to diagnose PAH, WHO group I classifi cation, and use of PAH-specifi c medications. After meeting enrollment criteria, no tests or study visits were required, but data were collected prospectively every 90 days, including PAH treatments, concomitant treatments, outcomes, and diagnostic procedures. Patients in open-label clinical trials had data collected; however, data collection was temporarily suspended for patients in blinded trials until completing the blinded portion of the study. The eDC system prompted quarterly updates with an option to indicate that the patient was not seen since the last update. Potential data inconsistencies were identifi ed primarily by the eDC system at the point of entry. Additional queries were generated by the data coordinating center. Sites were monitored for adherence to the protocol and resolution of data queries.
RHC Criteria
To be eligible, RHC had to have been performed before study entry and after the development of symptoms associated with PAH. Eligible patients were required to meet the following qualifying catheterization criteria: Although clinical trials often include only WHO group I patients with a PCWP of Յ 15 mm Hg, this registry used a less restrictive PCWP criterion of Յ 18 mm Hg to include patients seen in clinical practice. Patients who met catheterization criteria only with exercise were not required to meet the PVR criteria. 
Statistical Analysis
The target sample size for the study was 3,000 patients so that the study would have 80% power to detect a 20% survival difference in moderately sized subgroups of interest (eg, subgroups each representing 15%-25% of the total cohort). The cohort was designed to be suffi ciently large to address potential biases through stratification and statistical models. Per protocol, as enr ollment progressed, the proportions of newly and previously diag nosed patients were monitored to ensure that suffi cient numbers of newly diagnosed patients were enrolled. To achieve objectives related to newly diagnosed patients, the protocol was amended in mid-2007 to extend enrollment to include 500 additional newly diagnosed patients over 2 years who are not included in this analysis. Thus, this report describes a population that is representative of the patient demographics seen routinely at enrolling centers.
Percentages and means or medians are used to summarize categorical and continuous variables, respectively. The denominator for percentages is based on those patients with non-missing data. For percentages, standard errors (SEs) for the overall sample are less than 1 percentage point and SEs for small subgroups (ie, representing 10% of the full sample) are less than 2.5 percentage points.
Results
Demographics
A total of 3,052 patients with clinically suspected WHO group I PAH were screened. Of these, 2,977 patients (97.2%) were enrolled. Ten patients were subsequently determined to have had inadvertent duplication of data; the duplicate entries were discarded, thereby yielding a fi nal total of 2,967 patients. A total of 2,864 patients met the study entry criteria based on mean PAP, PCWP, and PVR at rest. Another 83 patients met the criteria at rest, substituting left Among patients on endothelin receptor antagonists at enrollment, 953 were on bosentan, 89 on ambrisentan, and 106 on sitaxsentan. Among patients on phosphodiesterase-5 inhibitors, 1,147 were on sildenafi l and 47 were on tadalafi l. A total of 1,012 patients were treated with a prostacyclin analog: treprostinil was given intravenously, subcutaneously, in inhaled form, and orally for 159, 112, 28, and 9 patients, respectively; 237 patients received inhaled iloprost; and 480 were treated with intravenous epoprostenol sodium.
Functional Class: Mean 6-min walk distance (6MWD) correlated well with functional class. The mean 6 SE 6MWD (in meters [m]) for functional classes I through IV were 475.5 6 9.3, 419.2 6 3.7, 323.1 6 3.8, and 214.1 6 13.7, respectively. There was, however, substantial overlap in walk distances for patients in the various functional classes. RHC parameters (eg, PVR [in Wood units]) were much less correlated with functional class (11.0 6 0.5, 11.5 6 0.3, 11.2 6 0.2, and 11.8 6 0.6 for functional classes I through IV, respectively).
Characteristics of Patients Outside of Traditional Hemodynamic Range for PAH
Adult patients meeting the traditional criterion of PCWP Յ 15 mm Hg were compared with the 239 adult patients with PCWP of 16 to 18 mm Hg at diagnosis ( Table 6 ). Patients with a PCWP of 16 to 18 mm Hg were older, more obese, had a lower 6MWD, and were more likely to have systemic hypertension, sleep apnea, renal insufficiency, and diabetes than adult patients meeting the traditional definition. Interestingly, they did not differ with respect to functional class or PAH treatments at enrollment. All statistically signifi cant differences between the two groups are shown in Table 6 .
Pediatric Patients
There were 200 pediatric patients enrolled whose age at diagnosis was Յ 18 years, with a mean age at diagnosis of 8.0 years and a mean age at enrollment of 15.1 years (interquartile range 5 8.6 to 20.0). One hundred thirty-four (67%) patients were female, and the majority saw a cardiologist at fi rst presentation. At the time of enrollment, 38 (21%) were in functional class I, 93 (52%) were in functional class II, 43 (24%) were in functional class III, and fi ve (3%) were in functional class IV. The mean 6MWD at enrollment was 429 6 134 m. As compared with adult patients with traditional hemodynamics (PCWP Յ 15 mm Hg), pediatric patients with traditional hemodynamics were less predominantly female, had a higher 6MWD, better functional RHC: The results of the RHC qualifying the patients for enrollment are shown in Table 2 . There were significant differences ( P , .001) between patients with IPAH and patients with associated PAH (APAH) for all hemodynamic criteria except for PCWP.
Comorbid Conditions: Comorbid conditions of patients meeting traditional hemodynamic criteria at enrollment are summarized in Table 3 . Among patients classifi ed by the enrolling investigator as drugs and toxins associated with PAH, a history of using fenfl uramines or fenfl uramine derivatives was noted for 57 of 78 patients for whom the suspected primary agent was an anorexigen and also for 74 of 1,166 (6%) and 2 of 69 (3%) of patients with IPAH and familial PAH (FPAH), respectively. A history of amphetamine use was noted for 53 of 55 (96%) patients for whom the suspected primary agent was a drug and also for 39 of 1,166 (3%) and 1 of 69 (1%) of patients with IPAH and FPAH, respectively. The transpulmonary pressure gradient (mean PAP minus mean PCWP) was slightly lower in patients with BMI Ն 30 kg/m 2 (40.7 6 13.1 mm Hg) compared with those with BMI , 30 kg/m 2 (42.1 6 13.8 mm Hg); with systemic hypertension (40.0 6 13.4 mm Hg) compared with those without hypertension (42.8 6 13.8 mm Hg); or with sleep apnea (41.0 6 12.7 mm Hg) compared with those without a diagnosis of sleep apnea (41.8 6 13.8 mm Hg). However, the transpulmonary pressure gradient in these patients was consistent with the defi nition of WHO group I PAH and indicated that markedly elevated precapillary resistance, rather than elevated pulmonary venous pressure, was the predominant cause of their PAH. The results were similar in the IPAH and APAH subgroups (data not shown).
Medications at Enrollment:
The PAH-specifi c treatments at the time of enrollment among patients meeting traditional hemodynamic criteria are shown in Table 4 . The concomitant medications taken by these patients at the time of enrollment are shown in Table 5 . Excluding calcium channel blockers, 266 patients were on no PAH therapies, 1,008 were on two or more drugs, and 183 were on three or more drugs. Of the 2,438 patients on any PAH treatment, 624 were taking calcium channel blockers. Of these, 212 (34.0%) were on calcium channel blockers specifi cally for PAH. Among 1,335 for whom results of a vasodilator challenge were known at enrollment, 136 patients were vasodilator responders and 55 of the responders (40.4%) were on calcium channel blockers for PAH. At enrollment, 16 of 124 (13%) functional class IV patients were not on any PAH-specifi c medications (excluding calcium channel blockers). Of these, 12 (75%) were newly diagnosed.
One striking fi nding is the marked female preponderance, which has increased over time in the United States. The NIH registry of primary pulmonary hypertension (or IPAH), 5 conducted in the mid-1980s, reported a 1.7:1 female-to-male ratio in the total cohort and a 4.3:1 ratio among blacks. The Surveillance of Pulmonary Hypertension in America registry, 25 conducted from 1998 to 2001 in the United States, reported a 4.3:1 ratio. The REVEAL Registry demonstrates a 4.1:1 female-to-male ratio among patients with IPAH, and a 3.8:1 ratio among those with APAH. A 5.4:1 ratio among 312 (12%) blacks supports the previous fi nding of higher female predominance. However, the French Registry, 23 conducted from October 2002 to October 2003, reported a 1.9:1 ratio. The reason for this demographic variability over time and between countries is unclear. A role for hormonal infl uences (particularly estrogens) in the pathogenesis of PAH has been considered. Estrogens may promote cellular proliferation; another disease involving the proliferation of smooth muscle cells within the lung, lymphangioleiomyomatosis, class, higher cardiac index, and fewer comorbidities, such as systemic hypertension, obesity, and sleep apnea.
Discussion
The REVEAL Registry is the largest and most comprehensive registry of WHO group I PAH reported to date. The size of the study (2,967 patients), the number of referral sites and community practices, and geographical distribution make the results generalizable to clinical practice. No center enrolled more than 10% of the population. Importantly, by using a less-restrictive PCWP criterion of Յ 18 mm Hg (as compared with the usual criterion of Յ 15 mm Hg), the registry intentionally included patients more typical of those currently seen in actual practice. Roughly half of the patients had idiopathic disease, and the other half had APAH. The most common underlying associated conditions were connective tissue disease and congenital heart disease. Values are mean 6 SD unless otherwise indicated. Hemodynamics at diagnostic RHC (baseline, at rest). CI 5 cardiac index; mPAP 5 mean pulmonary arterial pressure; PVRI 5 pulmonary vascular resistance index; RAP 5 right arterial pressure; RHC 5 right heart catheterization; SVO 2 5 mixed venous oxygen saturation. See Table 1 for expansion of other abbreviations. a This column refl ects all patients aged Ն 19 y at diagnosis with a PCWP Յ 15 mm Hg enrolled during the consecutive screening of newly and previously diagnosed patients, including those with WHO group I diagnoses other than IPAH or APAH (ie, FPAH, PVOD, and PPHN). b This column refl ects all APAH patients, including those with associated PAH subgroups other than CHD, CVD/CTD, portal HT, and drugs/toxins (ie, HIV and other). c APAH subgroups are mutually exclusive according to the following hierarchy for patients with multiple associate PAH diagnoses: CHD, CVD/ CTD, portal HT, drugs/toxins, HIV, and other. d The P value for all hemodynamic parameters is obtained from the two-sample t test examining the difference in the distribution of the characteristic among patients diagnosed with IPAH vs all patients with APAH. e Fick cardiac index is used unless it is missing, in which case thermodilution cardiac index is used. tension center persists. The median 1-year interval from symptom onset to RHC is due in part to the nonspecifi c manifestations of the disease; the registry confi rms the fact that dyspnea on exertion is the most common presenting symptom. Continued efforts to increase awareness among the public and clinicians are warranted.
The relationship between the mean 6MWD and functional class provides internal validation of the functional data obtained. However, there is variability in the 6MWD within each functional class, resulting in substantial overlap and supporting criticism that functional classifi cation is subjective and observerdependent. This is important in light of the fact that the current approach to therapy, based on Food and Drug Administration approvals and existing affl icts women exclusively. Although speculative, increased use of hormonal replacement therapy by women in the United States between the time of the NIH registry and the present 28,29 might have played a role in this apparent demographic shift.
The most common age of patients with PAH is bet ween 45 and 54 years, perhaps refl ecting improved survival on treatment. The population tends to be overweight, with a BMI of 29 kg/m 2 ; hence, obesity may be a risk factor for the development of PAH. The prevalence of recreational drug use, particularly cocaine and amphetamines, highlights emerging risk factors for the development of PAH and provides an opportunity for prevention.
Despite intensive educational efforts, a substantial delay in the referral of patients to a pulmonary hyper- h Includes patients with the comorbid condition hypothyroidism and/or patients with the reported use of "synthetic thyroid replacement treatment for hypothyroidism" as a concomitant medication. i Four types of cardiomyopathy are distinguished: dilated (n 5 24), hypertrophic (n 5 12), ischemic (n 5 11), restrictive (n 5 6), and one was unspecifi ed.
Thyroid disease, as noted in prior reports, [30] [31] [32] [33] [34] [35] was seen relatively frequently and may signal an underlying autoimmune process. As compared with patients meeting the traditional hemodynamic defi nition of PAH, patients with a PCWP of 16 to 18 mm Hg were older, more obese, had a lower 6MWD, and had a higher incidence of systemic hypertension, sleep apnea, renal insuffi ciency, and diabetes. These observations are consistent with patients who met this expanded hemodynamic defi nition having a higher incidence of systemic vascular and left heart disease. It is likely important to direct initial therapeutic efforts in this population toward these underlying comorbidities. Because these patients have typically been excluded from clinical trials, it remains to be determined whether such patients will respond favorably to PAH-specifi c therapies.
As compared with adult patients with traditional hemodynamics, pediatric patients were less predominantly female, had a higher 6MWD, better functional class, higher cardiac index, and fewer comorbidities, such as systemic hypertension, obesity, and sleep apnea. The absence of these underlying conditions suggests a primary pulmonary vasculopathy. Further comparisons treatment guidelines, 7-9 stratifi es patients based on functional class. There was not a tight association between functional class and severity of PAP elevation.
Cardiopulmonary hemodynamics were similar for IPAH and APAH. However, subgroup analysis demonstrated that patients with congenital heart disease had higher PAP but better cardiac output and exercise capacity than those with connective tissue disease. This fi nding supports the relative prognostic importance of right ventricular function and cardiac output as compared with PAP alone.
A variety of comorbid conditions were identifi ed, including systemic hypertension, obstructive lung disease, sleep apnea, and prior venous thromboembolism, which were not believed to represent the principal cause for the patients' pulmonary hypertension. Patients with PAH due to an underlying condition were classifi ed as having APAH or were excluded as being outside the diagnostic category of PAH. Systemic hypertension was the most commonly reported comorbid condition (40.2% of patients), perhaps refl ecting either a generalized vasculopathy or common substrate affecting both the pulmonary and systemic circulations, such as sleep apnea or diastolic dysfunction. Values are expressed as n (%). Combinations with one oral therapy, with one prostacyclin analog, and with more than one oral therapy are mutually exclusive and exclude calcium channel blockers. Blinded clinical trial patients are excluded from this presentation (No. 5 87). ETRA 5 endothelin receptor antagonist; NYHA 5 New York Heart Association; PDE-5 Inhibitor 5 phosphodiesterase inhibitor; SC 5 subcutaneous. See Table 1 for expansion of other abbreviations. a n 5 953 on bosentan, n 5 106 on sitaxsentan, and n 5 89 on ambrisentan. b n 5 1,147 on sildenafi l and n 5 47 on tadalafi l. c Treprostinil use includes n 5 159 on IV, n 5 112 on SC, n 5 28 on inhaled, and n 5 9 on oral treprostinil. d Oral therapy is defi ned as bosentan, sildenafi l, ambrisentan, sitaxsentan, and tadalafi l.
6MWD. 36 A trend toward increased benefi t with the addition of inhaled iloprost to bosentan therapy has been reported. 37 The widespread empirical use of combination therapy documented here emphasizes the importance of assessing the outcome of different treatment subgroups within the registry and supports the need for additional clinical trials to determine its value. Limitations of the registry include the small number of newly diagnosed cases compared with previously diagnosed cases. Although this somewhat compromises the interpretation of treatment data for new patients, this is being addressed by amendment of the protocol to permit the enrollment of another 500 newly diagnosed cases. Direct comparison of the baseline demographics of the REVEAL population to previous registries is complicated by the changing defi nition of PAH, the retrospective nature of enrollment, and the exclusion of pediatric patients from the analyses. These limitations are being addressed in subsequent analyses. [38] [39] [40] [41] Interpretation of therapeutic data is also limited by the uncontrolled nature of an observational study. Nevertheless, the large sample size, broad representation, and longitudinal follow-up help to ensure that the data obtained will complement those from clinical trials.
of adult and pediatric patients will require more detailed analysis.
The registry provides important insights into current treatment patterns. Only a small proportion of the patients enrolled were participating in randomized and controlled clinical trials, with a slightly larger number participating in open-label extension studies. Treatment with prostacyclin analogs increased with disease severity, as assessed by functional class. The most commonly used analog was intravenous epoprostenol, with smaller numbers of patients receiving inhaled iloprost or intravenously or subcutaneously administered treprostinil. Patients in functional classes II and III were commonly treated with oral agents, likely due to the simplicity and safety of this administration route.
The prevalence of combination therapy was high despite the paucity of randomized and controlled clinical trials evaluating the safety and effi cacy of such practice. The most commonly used combination, sildenafi l and bosentan, has not undergone validation in appropriately designed trials, although such a study is currently underway. The second most commonly used combination, epoprostenol and sildenafi l, has recently been studied; addition of sildenafi l to epoprostenol therapy was associated with further improvement in the has great potential to address several of the pressing needs in the fi eld, including better risk stratifi cation and the development and validation of more sophisticated prognostic tools. This will undoubtedly contribute to better targeting of medical therapy going forward.
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